These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6433325)

  • 41. Myeloprotective effects of different amifostine regimens in rabbits undergoing high-dose treatment with 186rhenium-(tin)1,1- hydroxyethylidene diphosphonate (186Re-HEDP).
    Brenner W; Kampen WU; Brümmer C; Von Forstner C; Zuhayra M; Muhle C; Czech N; Henze E
    Cancer Biother Radiopharm; 2003 Dec; 18(6):887-93. PubMed ID: 14969601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biodistribution studies of the 186Re complex of 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid in mice.
    Alyafei S; Tomiyoshi K; Sarwar M; Ahmed K; Zhang H; Oriuchi N; Inoue T; Endo K
    Nucl Med Commun; 1999 Jun; 20(6):551-7. PubMed ID: 10451868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of rhenium-188 HEDP in bone metastases therapy.
    Scheffler J; Derejko M; Bandurski T; Romanowicz G
    Nucl Med Rev Cent East Eur; 2003; 6(1):55-7. PubMed ID: 14600935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
    J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
    Binnie D; Divoli A; McCready VR; Dearnaley D; Flux G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):189-94. PubMed ID: 15869454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ESTIMATION OF HUMAN DOSE OF 188/186RE-HEDP COCKTAIL BASED ON OLINDA/EXM AND DISTRIBUTION DATA IN RATS.
    Pourhabib Z; Ranjbar H; Bahrami Samani A
    Radiat Prot Dosimetry; 2020 Aug; 190(2):158-164. PubMed ID: 32626897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.
    Lange R; de Klerk JMH; Bloemendal HJ; Ramakers RM; Beekman FJ; van der Westerlaken MML; Hendrikse NH; Ter Heine R
    Nucl Med Biol; 2015 May; 42(5):465-469. PubMed ID: 25662844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rhenium-186 HEDP as a boost to external beam irradiation in osteosarcoma.
    Sawyer EJ; Cassoni AM; Waddington W; Bomanji JB; Briggs TW
    Br J Radiol; 1999 Dec; 72(864):1225-9. PubMed ID: 10703485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigation of two new [99mTc]Tc-HEDP preparations that can be expected to give a better lesion-to-normal-bone uptake ratio when used as bone scanning agents.
    de Ligny CL; Gelsema WJ; Hoevelaken TP; Schuring J
    Nucl Med Biol; 1993 Jan; 20(1):23-9. PubMed ID: 8461877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo distributions of some component fractions of Tc(NaBH4)-HEDP mixtures separated by anion exchange high performance liquid chromatography.
    Pinkerton TC; Ferguson DL; Deutsch E; Heineman WR; Libson K
    Int J Appl Radiat Isot; 1982 Oct; 33(10):907-15. PubMed ID: 6818160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of DMSO treatment on the performance of [99mTc]HEDP.
    Bugaj JE; Esser PD; Tofe AJ; Borgia AT; Fawwaz RA
    Int J Nucl Med Biol; 1984; 11(2):109-11. PubMed ID: 6434460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
    van der Poel HG; Antonini N; Hoefnagel CA; Horenblas S; Valdes Olmos RA
    Urol Int; 2006; 77(1):50-6. PubMed ID: 16825816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
    J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of complex charge and size on the uptake of 99mTc-diphosphonates in osteogenic tissue.
    Pinkerton TC; Cheng KT; Shaw SM; Wilson GM
    Int J Rad Appl Instrum B; 1986; 13(1):49-56. PubMed ID: 3095270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
    Quirijnen JM; Han SH; Zonnenberg BA; de Klerk JM; van het Schip AD; van Dijk A; ten Kroode HF; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Sep; 37(9):1511-5. PubMed ID: 8790203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 186Re-etidronate in breast cancer patients with metastatic bone pain.
    Han SH; Zonneberg BA; de Klerk JM; Quirijnen JM; van het Schip AD; van Dijk A; Blijham GH; van Rijk PP
    J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes.
    Lin WY; Hsieh JF; Lin CP; Hsieh BT; Ting G; Wang SJ; Knapp FF
    Nucl Med Biol; 1999 May; 26(4):455-9. PubMed ID: 10382850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Advanced prostate carcinoma: systemic radionuclide therapy of bone metastasis with rhenium-168-hydroxyethylidine diphosphonate].
    Lerch H
    Strahlenther Onkol; 1998 Jul; 174(7):384-5. PubMed ID: 9689963
    [No Abstract]   [Full Text] [Related]  

  • 60. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma.
    Syed R; Bomanji J; Nagabhushan N; Kayani I; Groves A; Waddington W; Cassoni A; Ell PJ
    J Nucl Med; 2006 Dec; 47(12):1927-35. PubMed ID: 17138735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.